{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"743.0","value":"1969.6"},{"groupId":"OG001","spread":"685.6","value":"2120.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"318"}],"units":"Participants"}],"description":"AUC was assessed on Cycle 1 Day 1, Cycle 2 Day 1 and Cycle 1 Day 15. Summarized data for all time points was reported. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received lenvatinib capsules 12 mg based on the participant's body weight \\>=60 kg or 8 mg based on the participant's body weight \\<60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.","id":"OG000","title":"Lenvatinib 8 mg"},{"description":"Participants received lenvatinib 12 mg capsules based on the participant's body weight (\\>=60 kg) at Baseline, orally, once daily in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.","id":"OG001","title":"Lenvatinib 12 mg"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic (PK) analysis set included all participants who had received at least 1 dose of lenvatinib and had at least 1 quantifiable lenvatinib concentration.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1, Cycle 2 Day 1: pre-dose, 0.5-4 and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 2-12 hours post-dose (cycle length= 28 days)","title":"Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib","type":"SECONDARY","unitOfMeasure":"nanogram*hour per milliliter (ng*h/mL)"}